Kriya Announces $320 Million Series D Financing to Advance Pipeline of Gene Therapies for Chronic Diseases of High Unmet Need

– Proceeds to support clinical trials of Kriya’s five lead pipeline programs, as well as the Company’s R&D and man­u­fac­tur­ing engine for new product development –

RESEARCH TRIANGLE PARK, N.C. – September 10, 2025 – Kriya Ther­a­peu­tics, Inc. (“Kriya”), a clinical-stage bio­phar­ma­ceu­ti­cal company developing gene therapies to address common chronic diseases of high unmet need, today announced the closing of a $320 million Series D financing. The round was co-led by Patient Square Capital and Premji Invest, with par­tic­i­pa­tion from other leading life sciences and technology-focused investors including Peter Thiel, Narya Capital, The T1D Fund: A Break­through T1D Venture, LLC and other long- term investors. The round was over­sub­scribed and completed at a significant step up to the previous round of financing. Akshay Rai from Premji Invest has joined Kriya’s Board of Directors in conjunction with this financing.

Proceeds from this financing will support clinical trials of Kriya’s gene therapies in multiple therapeutic areas, as well as the continued utilization of the Company’s research and man­u­fac­tur­ing engine for new product development. Kriya’s pipeline includes focally delivered gene therapies for chronic diseases, including Geographic Atrophy, Thyroid Eye Disease, Type 1 Diabetes, Metabolic Associated Steato­hep­ati­tis (MASH) and Trigeminal Neuralgia. The Company’s pipeline is supported by its industry-leading integrated man­u­fac­tur­ing and R&D engine dedicated to estab­lish­ing new standards of excellence for gene therapy purity, scale and production cost.

“Our investment thesis to co-lead Kriya’s Series D financing centered on the company’s advanced man­u­fac­tur­ing platform, built to support the development and com­mer­cial­iza­tion of gene therapies for prevalent diseases in large markets,” said Akshay Rai, Healthcare and Biotech Investor at Premji Invest. ​“Man­u­fac­tur­ing constraints have his­tor­i­cal­ly limited the evolution of the gene therapy field, and we believe that Kriya has solved these challenges by metic­u­lous­ly building its fully-integrated CMC engine — evidenced by its ability to advance in parallel several first-ever gene therapy candidates for multiple chronic diseases.”

Jim Momtazee, Managing Partner of Patient Square Capital, added, ​“We have been proud to support Kriya since Patient Square led the company’s Series B funding round in 2021 and have been impressed with the team’s vision and the platform’s scientific and commercial potential. This financing marks an important inflection point as the company advances its clinical programs, and we are excited to continue working with the team to move those programs forward.”

About Kriya Ther­a­peu­tics
Our mission is to rev­o­lu­tion­ize medicine, with the ultimate goal of eliminating human suffering and enabling people to live without the burden of disease. Kriya is a clinical-stage bio­phar­ma­ceu­ti­cal company developing gene therapies to address chronic diseases affecting millions of people around the world. Our pipeline includes potentially trans­for­ma­tion­al medicines in multiple therapeutic areas — including in oph­thal­mol­o­gy, metabolic disease and neurology — built on our fully-integrated proprietary man­u­fac­tur­ing and engineering platform. For more information, please visit www​.kriyatx​.com and follow us on LinkedIn and Twitter.

Media Contact:
Kelli Perkins
kelli@​redhousecomms.​com